PRKAA1 and breast carcinoma: While AMPK has been proposed as a therapeutic target in breast cancer and is recognized to inhibit many of the pathways regulated by tyrosine kinase growth factor receptors [18], evidence to date has not shown a direct mechanism for this inhibition.